Teva (TEVA) Q1 2026 earnings review
Innovative Brands Eclipse Generics, but Revlimid Cliff and M&A Drag Earnings
Teva's 'Pivot to Growth' strategy hit a major inflection point in Q1: key U.S. innovative brands (AUSTEDO, UZEDY, AJOVY) collectively surpassed U.S. Generics revenue for the first time. However, the headline 2% YoY revenue growth masks a 3% local currency contraction, exposing the painful reality of the anticipated generic Revlimid patent cliff (U.S. Generics crashed 28%). While the $700M acquisition of Emalex Biosciences adds a highly promising late-stage Tourette syndrome asset, the resulting IPR&D charge guts FY26 EPS guidance. Teva is successfully transforming its portfolio mix, but the transition period remains messy for the bottom line.
🐂 Bull Case
AUSTEDO, UZEDY, and AJOVY are accelerating rapidly, collectively growing 41% YoY in local currency. UZEDY in particular jumped 62%, proving Teva's ability to commercialize complex, long-acting injectables.
The Emalex acquisition brings ecopipam, a first-in-class, NDA-ready asset for Tourette syndrome, perfectly aligning with Teva's neuroscience focus and offsetting the loss of exclusivity on older generics.
🐻 Bear Case
Stripping out a massive $219M favorable FX impact, Teva's global revenue actually fell 3% YoY. The core business is shrinking under the weight of the generic Revlimid loss.
The Emalex deal requires a $700M IPR&D charge and adds operating expenses, slashing the midpoint of FY26 Non-GAAP EPS guidance from $2.67 (standalone) to $2.01. Free cash flow generation must remain pristine to absorb this capital outlay.
⚖️ Verdict: ⚪
Neutral. The portfolio transition is undeniably working as innovative drugs replace low-margin generics. However, a local-currency revenue contraction and the heavy near-term EPS dilution from the Emalex acquisition mean investors will need patience to see the bottom-line benefits.
Key Themes
Data Contradicts Narrative: Local Currency Contraction
Management highlighted a 2% USD revenue growth as proof of disciplined execution, but the reality is Reversing: in local currency, total revenue dropped 3% YoY. A $219M positive currency fluctuation (including hedging) artificially propped up the top line and contributed $71M to operating income. This macro FX tailwind is masking the severity of the generic portfolio's decline.
The Generic Revlimid Cliff Materializes
The highly anticipated generic Revlimid (lenalidomide) headwind has arrived with full force. U.S. generic product revenues plummeted 28% YoY to $612M. This Decelerating trend in the base business is forcing the innovative portfolio to work twice as hard just to keep total company revenues flat.
AUSTEDO and UZEDY Lead the Growth Charge
The innovative neuroscience portfolio is Accelerating. AUSTEDO global revenues hit $578M (+41% LC YoY), maintaining its status as Teva's primary growth engine. More impressively, UZEDY (risperidone LAI) reached $63M (+62% LC YoY), validating management's claim that it is the fastest-growing LAI and is nearly doubling the overall risperidone market since launch.
Emalex Acquisition Secures Near-Term Pipeline Catalyst
Teva is acquiring Emalex Biosciences for $700M upfront (plus up to $200M in milestones) to secure ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. With Phase 3 data already showing statistical significance and an NDA submission anticipated in H2 2026, this significantly bolsters Teva's neuroscience pipeline.
Significant Near-Term Earnings Dilution
The Emalex deal comes at a steep near-term cost. FY26 Non-GAAP EPS guidance was revised from a standalone midpoint of $2.67 down to $2.01. The $0.66 per share hit stems from an expected $700M IPR&D charge and $75M in ongoing operating/transaction expenses. Management must flawlessly execute the ecopipam launch to justify this severe near-term profitability hit.
Biosimilar Portfolio Expanding
Biosimilars are providing a critical counterweight to traditional generic price erosion. Teva secured FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, across all indications. Additionally, their biosimilar candidate for Xolair (omalizumab) was accepted for review in both the U.S. and EU. Management reiterated their target to reach $800M in biosimilar revenues by 2027.
Other KPIs
Accelerating. Up significantly from $107 million in 25Q1. Operating cash flow improved drastically (-$40M vs -$105M YoY) due to favorable timing of sales and collections in the U.S. segment. This cash generation is critical as Teva prepares to fund the $700M cash upfront payment for Emalex.
Stable. Up marginally from 52.8% in 25Q1. The margin profile remains resilient despite the massive 28% drop in U.S. generics, entirely saved by the mix shift toward high-margin innovative drugs like AUSTEDO.
Total debt sits at $16.62 billion, slightly down from $16.80 billion at year-end 2025. Short-term debt increased to 16% of total debt (up from 11% at year-end). The average debt maturity slightly compressed to 5.4 years. Deleveraging progress remains slow but steady.
Guidance
Decelerating. Compared to FY25 reported revenues of $17.25 billion, the midpoint of $16.6 billion implies a year-over-year contraction of roughly 3.8%. This reflects the full-year drag of the generic Revlimid loss.
Reversing. Down drastically from the $4.9 billion generated in FY25. This entire drop is artificial, driven by the $700M IPR&D charge for the Emalex acquisition. Standalone guidance ($4.55 - $4.8B) still implies a slight deceleration vs FY25 due to generic headwinds.
Decelerating. Standalone guidance is $5.0 - $5.3 billion, which would be flat-to-down compared to the $5.3 billion achieved in FY25. The inclusion of Emalex transaction costs drops the reported range significantly.
Stable. In line with the $2.39 billion generated in FY25. Maintaining this level of cash generation despite the Revlimid cliff and Emalex integration costs is vital for ongoing debt servicing.
Key Questions
Emalex Integration and Margin Recovery
With the $700M upfront cost and $75M in FY26 operating expenses for Emalex, how does this alter the trajectory toward your stated goal of a 30% operating margin by 2027? Is that target still achievable?
U.S. Generics Baseline
U.S. generics collapsed 28% this quarter largely due to Revlimid. When do you expect the U.S. generic business to reach a normalized run-rate where biosimilar launches can actually drive segment growth rather than just plug holes?
Underlying Revenue Contraction
Excluding the highly favorable FX impact this quarter, local currency revenues fell 3%. How much of this is structural due to European pricing and the Japan divestiture, and when will innovative volume overcome this baseline erosion in constant currency?